Dynavax reported a strong second quarter in 2024, marked by record HEPLISAV-B net product revenue and the initiation of a Phase 1/2 trial for its novel shingles vaccine program. The company is optimistic about the adult hepatitis B vaccine market and continues to evaluate strategic opportunities for growth.
Achieved record quarterly HEPLISAV-B® net product revenue of $70.2 million, growing 24% year-over-year.
Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million.
Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025.
HEPLISAV-B total estimated market share in the U.S. increased to approximately 42%.
Dynavax is reiterating its full year 2024 financial guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance